Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 1997

View Archived Issues

Indian investigators prepare novel hypolipidemic agents

Novel LTB4 receptor antagonist described

Schering AG investigates vitamin D derivatives

SKB prepares chimeric leptins

Antitumor heterocyclic compounds from Takeda

Akzo reports peptides for specific tolerance therapy

Zambon discloses ACE/NEP inhibitors

Antifungals from Schering-Plough

PFT inhibitors described by Warner-Lambert

Biorex discloses antiischemic agents

Subtype-selective 5-HT1 antagonists from Pierre Fabre

Anergen reports 1996 financial results

InSite Vision releases 1996 earnings

Interneuron announces first-quarter fiscal 1997 results

Targeted Genetics reports fourth-quarter 1996 financial results

Schering-Plough seeks FDA approval for psoriasis treatment

Xytronyx reports fiscal 1997 third-quarter results

Cortex seeks AMPAkine patent approval

Vasogen to extend clinical trials with VasoCare

New agreement reached for Searle's Maxaquin

AnorMED receives funding for cancer imaging

SIBIA Neurosciences initiates clinical trials of antiparkinsonian product

Immunotherapy cancer vaccine in phase II

Athena Neurosciences and Lilly extend research collaboration

Glaxo Wellcome discovers potent, selective CCK-B/gastrin antagonist

Novel kappa-opioid agonist from Parke-Davis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...